Skip to main content

Neurocysticercosis

2
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 3 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Allied Medical
Allied MedicalMO - St. Louis
2 programs
1
albendazole and praziquantelPhase 41 trial
Diagnosis ofN/A1 trial
Active Trials
NCT03851419Completed2,584Est. Apr 2021
NCT06376396Not Yet Recruiting300Est. Dec 2026
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
1
AlbendazolePhase 3Small Molecule1 trial
People Presenting With Neurocysticercosis in North AmericaN/A1 trial
Active Trials
NCT02233855Terminated11Est. Jun 2017
NCT00290823Completed110Est. Mar 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allied Medicalalbendazole and praziquantel
Allergy TherapeuticsAlbendazole
Allied MedicalDiagnosis of
Allergy TherapeuticsPeople Presenting With Neurocysticercosis in North America

Clinical Trials (4)

Total enrollment: 3,005 patients across 4 trials

NCT06376396Allied Medicalalbendazole and praziquantel

Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis

Start: Jun 2024Est. completion: Dec 2026300 patients
Phase 4Not Yet Recruiting
NCT00290823Allergy TherapeuticsAlbendazole

Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients

Start: Apr 2006Est. completion: Mar 2011110 patients
Phase 3Completed
NCT03851419Allied MedicalDiagnosis of

The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania

Start: Apr 2018Est. completion: Apr 20212,584 patients
N/ACompleted
NCT02233855Allergy TherapeuticsPeople Presenting With Neurocysticercosis in North America

People Presenting With Neurocysticercosis in North America

Start: Sep 2014Est. completion: Jun 201711 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.